GlassScriptPhysician profile
Brandon G Stalzer
NPI 1215925227
$2,742.12
in general payments reported to CMS, 2019-2025
21 companies · $708 in 2025
The $708 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $65.91 · 2021: $132 · 2022: $332 · 2023: $371 · 2024: $875 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,936 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.31 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $607.41 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $603.38 | 2019-2025 | Clareon, Argos |
| Abbvie INC. | $349.28 | 2022-2025 | Alphagan P, Vuity, Lumigan |
| Regeneron Healthcare Solutions, INC. | $190.28 | 2019-2025 | Eylea Hd, Eylea |
| Tarsus Pharmaceuticals, INC. | $163.88 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $147.27 | 2019-2025 | |
| Rayner Intraocular Lenses Limited | $122.05 | 2022-2024 | Omidria, Rayone Spheric, Rayone Emv |
| Novartis Pharmaceuticals Corporation | $118.27 | 2019-2023 | |
| Biotissue Holdings INC. | $79.12 | 2022 | |
| Oyster Point Pharma, INC. | $44.43 | 2024-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.28 | 2019 | |
| Harrow Eye, LLC | $39.77 | 2024 | Iheezo |
| Shire North American Group INC | $39.48 | 2019 | |
| Amgen INC. | $36.74 | 2025 | Tepezza |
| Allergan, INC. | $36.01 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $33.67 | 2025 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $23.49 | 2021 | |
| The Cameron-Ehlen Group, INC. | $17.12 | 2020 | |
| Glaukos Corporation | $16.93 | 2025 | Istent Infinite |
| Sun Pharmaceutical Industries INC. | $15.19 | 2020 | |
| Kala Pharmaceuticals, INC. | $14.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Stalzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.